Company news

Grifols, S.A. news in 2024

Grifols, S.A.'s news releases, calls and decks from 2024, newest first.

View company

Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years

July 1, 2024

Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies

June 17, 2024

Procleix ArboPlex Assay® di Grifols, primo e unico test NAT 4-in-1 per lo screening degli arbovirus, riceve il marchio CE

April 4, 2024

Procleix ArboPlex Assay® da Grifols recebe a marca CE, o primeiro e único NAT 4 em 1 para o rastreio de arbovírus

April 4, 2024

Le test Procleix ArboPlex Assay® de Grifols, test de Dépistage Génomique Viral 4-en-1 destiné au dépistage des arbovirus, reçoit le marquage CE

April 4, 2024

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

April 4, 2024

Grifols Procleix ArboPlex Assay® erhält die CE-Zertifizierung – der erste und einzige 4-in-1-Nukleinsäuretest zum Nachweis von Arboviren

April 4, 2024

Grifols announces positive topline phase 3 fibrinogen clinical trial results

February 14, 2024

Calls in 2024

Decks in 2024